ADMINISTRATION VASCULAIRE LOCALE DE 2-METHOXYESTRADIOL EN COMBINAISON AVEC LA RAPAMYCINE AFIN DE PREVENIR UNE RESTENOSE A LA SUITE D'UNE LESION VASCULAIRE
Medical devices, and in particular implantable medical devices, may be coatedtominimize or substantially eliminate a biological organism's reaction to theintroduction of the medical device to the organism. The medical devices may becoated with any number of biocompatible materials. Therapeutic drugs, agentsorcompounds may be mixed with the biocompatible materials and affixed to atleasta portion of the medical device. in addition, various polymer combinations maybeutilized to control the elution rates of the therapeutic drugs, agents and/orcompounds from the implantable medical devices. The medical device isdisclosed that comprises an implantable structure, a basecoat matrix and atopcoat. The basecoat matrix includes a combination of rapamycin and2- methoxyestradiol, in therapeutic dosages, incorporated in a first polymericmaterial.The basecoat matrix is affixed to the surface of the implantable medicaldevice.The topcoat includes a second polymeric material. The topcoat is affixed tothebasecoat matrix for controlling the elution rate of the rapamycin and 2-methoxyestradiol.
